<DOC>
	<DOCNO>NCT01953159</DOCNO>
	<brief_summary>The purpose study collect clinical data , blood sample , self report symptoms patient experience unusually severe neuropathy treatment paclitaxel . This data use develop predictive marker neuropathy . Blood sample use create induced pluripotent stem ( iPS ) cell eventually artificial nerve cell use study neuropathy lab .</brief_summary>
	<brief_title>Assessment Paclitaxel-Induced Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria ( Severe Toxicity Group ) : Diagnosis cancer ( include , limited , breast ovarian cancer ) Females age 18 old History grade 3 high peripheral neurotoxicity , neuromotor , neurocortical , neurocerebellar toxicity , myalgias arthralgias refractory nonsteroidal antiinflammatory drug steroid , ongterm persistence ( &gt; 6 month ) grade 2 high peripheral neuropathy , unusually severe neurotoxicity approve inclusion study Principal Investigator completion paclitaxel chemotherapy regimen history peripheral neuropathy require treatment narcotic grade 2 high peripheral neuropathy 1 2 dos paclitaxel . Inclusion Criteria ( Control Group ) : History neurotoxicity ( grade 0 ) completion standard paclitaxelcontaining chemotherapy regimen Females age 18 old Matched specify subject neurotoxicity base age ( within 10 year ) , tumor type , chemotherapy regimen total paclitaxel dosage , race , ethnicity Exclusion Criteria : Treatment severely neurotoxic chemotherapy ( i.e . cisplatin ) prior concomitantly paclitaxel . Carboplatin therapy allow . Presence peripheral neuropathy prior paclitaxel therapy Poorly control insulindependent diabetes condition likely predispose neurotoxicity ( alcoholism , CharcotMarieTooth disease )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>